ImmunoPrecise Confirms Success of AI-Driven Universal Dengue Vaccine Target, Showing Safety and Strong Immune Response

ImmunoPrecise Advances Universal Dengue Vaccine Development with LENSai™ Platform and HYFT® Technology AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise (NASDAQ: IPA), a pioneering company in AI-driven biotherapeutics, has announced significant progress in its universal dengue vaccine development. Following the initial breakthrough disclosed in a press release on June 5, 2023, the company has now validated the epitope identified using its LENSai™ platform powered by patented HYFT® technology. The downstream validation confirms that the computationally selected vaccine target is highly conserved across all four serotypes of the dengue virus. This finding is crucial as it indicates that the vaccine can potentially provide broad protection against the varied strains of the virus, which is a significant challenge in dengue vaccine development. The validation process also demonstrated that the epitope effectively activates the immune system and maintains structural stability, essential attributes for a viable vaccine candidate. "This advance represents a major milestone in our mission to develop a universal dengue vaccine," said Dr. Jennifer Bath, CEO of ImmunoPrecise. "By leveraging our cutting-edge AI and proprietary HYFT® technology, we have identified a promising target that addresses key hurdles in vaccine research. We are excited to proceed with further preclinical studies to bring this potential solution closer to clinical trials." The LENSai™ platform uses advanced AI algorithms to predict and identify optimal epitopes, which are specific parts of a virus that trigger an immune response. The HYFT® technology ensures that these epitopes are structurally stable, enhancing their effectiveness and reliability. Together, these technologies provide a powerful tool for accelerating the discovery and development of new vaccines. ImmunoPrecise’s progress in this area comes at a critical time, as dengue fever poses a significant global health threat, affecting millions of people annually. Current dengue vaccines on the market offer limited protection and have safety concerns, making the search for a universal and safer vaccine paramount. The company plans to conduct additional preclinical studies to further validate the safety and efficacy of the identified epitope. These studies will pave the way for potential human clinical trials, bringing the world one step closer to a comprehensive solution for preventing dengue fever. ImmunoPrecise's commitment to using AI and proprietary technology to tackle complex global health challenges underscores its role as a leader in the biotechnology sector. With continued advancements, the company aims to contribute significantly to the fight against infectious diseases.